Bristol-Myers Squibb Co. (BMY)

52.12
NYSE : Health Technology
Prev Close 53.64
Day Low/High 51.93 / 53.26
52 Wk Low/High 46.94 / 70.05
Avg Volume 8.28M
Exchange NYSE
Shares Outstanding 1.63B
Market Cap 87.22B
EPS 0.60
P/E Ratio 60.27
Div & Yield 1.64 (2.99%)

Latest News

Bristol-Myers Squibb Announces Dividend Increase

Bristol-Myers Squibb Announces Dividend Increase

The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb To Announce Results For Fourth Quarter 2018 On January 24

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2018 on Thursday, January 24, 2019.

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb To Transfer $3.8 Billion In U.S. Pension Liabilities

Bristol-Myers Squibb Company (NYSE: BMY) today announced it will transfer $3.8 billion of U.

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb To Highlight New Data From Broad Oncology Portfolio At The 60th American Society Of Hematology Annual Meeting

Bristol-Myers Squibb Company (NYSE:BMY) today announced that 19 data presentations and publications, including two oral presentations, from Company-sponsored studies and collaborations evaluating Opdivo (nivolumab), Sprycel (dasatinib) and Empliciti...

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb To Take Part In Citi 2018 Global Healthcare Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York.

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Bristol-Myers Drops After Lung-Cancer Drug Study Fails

Shares decline after the company says a lung-cancer study it had been working on failed.

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Announces CheckMate -451 Study Did Not Meet Primary Endpoint Of Overall Survival With Opdivo Plus Yervoy Vs. Placebo As A Maintenance Therapy In Patients With Extensive-Stage Small Cell Lung Cancer After Completion Of First-Line Chemotherapy

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Phase 3 CheckMate -451 study did not meet its primary endpoint of overall survival (OS) with Opdivo (nivolumab) 1 mg/kg in combination with Yervoy (ipilimumab) 3 mg/kg versus placebo as a...

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Awards "Golden Tickets" For LabCentral To ReviveMed, Strand Therapeutics

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that ReviveMed and Strand Therapeutics are the winners of Bristol-Myers...

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb To Take Part In Evercore ISI HealthCONx Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018, in Boston.

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) As First-Line Treatment For Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo® (nivolumab) Plus Low-Dose Yervoy® (ipilimumab) As First-Line Treatment For Patients With Intermediate- And Poor-Risk Advanced Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE: BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending approval of the Opdivo (nivolumab) plus low-dose Yervoy...

Drug Stocks Climb as Investors Digest Midterm Election Results

Drug Stocks Climb as Investors Digest Midterm Election Results

A split Congress is the best-case scenario for the drug industry, several analysts said.

Bristol-Myers Squibb To Take Part In Credit Suisse 2018 Health Care Conference

Bristol-Myers Squibb To Take Part In Credit Suisse 2018 Health Care Conference

Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Credit Suisse Annual Health Care Conference on Wednesday, November 14, 2018 in Scottsdale, AZ.

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb And Infinity Pharmaceuticals Announce A New Clinical Collaboration To Evaluate Opdivo (Nivolumab) In Combination With IPI-549 In Urothelial Cancer

Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial...

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

A One-Two Punch to the Bears: Cramer's 'Mad Money' Recap (Thursday 11/1/18)

Jim Cramer's been saying that that if the Fed or the president blink in their wars against inflation and China you could have an up day. That's what we got.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

Dow Closes 400 Points Higher as Wall Street Rebounds on Earnings

The Dow Jones Industrial Average snaps back solidly Thursday after plunging more than 600 points in the previous session.

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Beats Q3 Earnings, Boosts Full-Year Outlook on Solid Opdivo Sales

Bristol-Myers Squibb posts stronger-than-expected third-quarter earnings Thursday and boosts its full-year profit outlook.

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global Stock Sell-Off Wipes Trillions From Markets; US Futures Look To Rebound

Global stocks were awash with red in overnight trading Thursday, loping billions in value from equity markets around Asia following last night's late-trading collapse on Wall Street which has erased year-to-date gains for benchmarks around the world amid concerns over weakening U.S. earnings growth, rising geo-political tensions and the unknown outcome of trade disputes between Washington and its major economic partners.

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

Here Are 9 Takeaways From Last Night's Meltdown: Market Recon

It becomes difficult for me to tell you where to run in these markets...

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

Halozyme Announces First Clinical Dosing In Bristol-Myers Squibb's Phase 1 Trial Of BMS-986179 With Enhanze® Technology

SAN DIEGO, Oct. 25, 2018 /PRNewswire/ -- Halozyme Therapeutics, Inc.

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Reports Third Quarter Financial Results

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the third quarter of 2018 which were highlighted by strong sales and operating performance along with key regulatory and clinical milestones across the portfolio.

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

Jim Cramer: Avoid the Naked CEOs When the Tide Goes Out

There is clear divergence between the best and the worst performers in each sector this earnings season.

Mirati Shares Fall After Cancer Trial Progress Report

Mirati Shares Fall After Cancer Trial Progress Report

Shares of Mirati Therapeutics fell Monday after the drug developer released a progress report of an early stage clinical trial of its lung cancer drug used in conjunction with a Bristol-Myers Squibb Co. medication.

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Bristol-Myers Slides After FDA Delays Marketing Approval for Cancer Therapy

Bristol-Myers Squibb fall sharply after the U.S. Food & Drug Administration extends the approval date for a combination-drug treatment for lung cancer patients.

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Dow Trades Lower After Momentum From China Rally Fades, Nasdaq Rises

Stocks are mixed after rising earlier in the session following a rally in China that saw stocks soar to their biggest single-day gain in nearly three years.

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Opdivo (nivolumab) In Combination With Yervoy (ipilimumab) Results In Significantly Longer Treatment-Free Survival In Patients With Previously Untreated Advanced Or Metastatic Renal Cell Carcinoma

Bristol-Myers Squibb Company (NYSE:BMY) today announced the results of a new analysis from the Phase 3 CheckMate -214 study, demonstrating that therapy with Opdivo (nivolumab) plus Yervoy (ipilimumab) in patients with previously untreated advanced or...

TheStreet Quant Rating: C+ (Hold)